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ABSTRACT
We have established an in vitro reconstitution/splicing
complementation system which has allowed the inves-
tigation of the role of mammalian U1 snRNP compo-
nents both in splicing and at the early stages of
spliceosome formation. U1 snRNPs reconstituted from
purified, native snRNP proteins and either authentic or
in vitro transcribed U1 snRNA restored both early (E)
splicing complex formation and splicing activity to
U1-depleted extracts. In vitro reconstituted U1 snRNPs
possessing an m3G or ApppG cap were equally active
in splicing, demonstrating that a physiological cap
structure is not absolutely required for U1 function.
However, the presence of an m7GpppG or GpppG cap
was deleterious to splicing, most likely due to competi-
tion for the m7G cap binding proteins. No significant
reduction in splicing or E complex formation was
detected with U1 snRNPs reconstituted from U1
snRNA lacking the RNA binding sites of the U1-70K or
U1-A protein (i.e., stem–loop I and II, respectively).
Complementation studies with purified HeLa U1
snRNPs lacking subsets of the U1-specific proteins
demonstrated a role for the U1-C, but not U1-A, protein
in the formation and/or stabilization of early splicing
complexes. Studies with recombinant U1-C protein
mutants indicated that the N-terminal domain of U1-C
is necessary and sufficient for the stimulation of E
complex formation.
INTRODUCTION
Nuclear pre-mRNA splicing requires the formation of a large
ribonucleoprotein complex, the spliceosome, wherein the catalysis
of the two sequential transesterification reactions responsible for
intron removal and exon ligation occurs. Spliceosomes are
formed by the ordered interaction of numerous splicing factors
and the four small nuclear ribonucleoproteins (snRNPs), U1, U2,
U5 and U4/U6, with conserved regions of the pre-mRNA
(reviewed in 1). One of the initial contacts with the pre-mRNA in
the spliceosome assembly pathway is the binding of U1 snRNP
to the 5′ splice site. This interaction involves base pairing between
the 5′ end of the U1 snRNA and conserved sequences spanning
the 5′ splice site (2,3). A stable U1 snRNP/pre-mRNA complex,
referred to as the commitment complex, was first identified in
yeast (4,5). A similar complex, designated the early or E complex,
was subsequently identified in mammalian splicing extracts by
gel filtration (6,7). Subsequent to E complex assembly, the U2
snRNP interacts with the branch site of the intron, thereby
forming the so-called pre-spliceosome. Mature spliceosomes are
ultimately formed by the interaction of the U4/U6 and U5
snRNPs, in the form of a pre-assembled [U4/U6.U5] tri-snRNP
complex (reviewed in 1).
The spliceosomal snRNPs consist of one snRNA molecule (or
two in the case of U4/U6) complexed with eight so-called Sm or
core proteins (B, B′, D1, D2, D3, E, F, G), which are present in
all snRNP species, and a number of particle-specific proteins
(reviewed in 8). The snRNP core proteins interact with an
evolutionarily conserved region of the U1, U2, U4 and U5
snRNAs, the Sm site, which consists of a single-stranded, uridylic
acid-rich region that is flanked by two stem–loop structures (9).
The association of the snRNP Sm proteins results in the
hypermethylation of the snRNA’s monomethylguanosine (m7G)
5′ cap structure to a 2,2,7-trimethylguanosine (m3G) form (10).
The m3G cap, together with the snRNP Sm proteins, forms the
karyophilic signal required for the nuclear import of the
spliceosomal snRNPs (11,12).
The mammalian U1 snRNP contains, in addition to U1 snRNA
and the common snRNP proteins, three U1-specific proteins
denoted 70K, A and C. The U1-70K and U1-A proteins possess
highly conserved RNA binding domains (RBDs) characteristic of
a number of RNA binding proteins (13,14). These proteins are
thus able to interact directly with the U1 snRNA; specifically,
U1-70K binds stem–loop I of the U1 snRNA and U1-A interacts
with stem–loop II (15–17). Protein–protein contacts also appear
to contribute to the association of U1-70K and U1-A with the U1
particle. For example, a stable interaction between a U1-70K
deletion mutant containing the N-terminal 97 amino acids, which
do not bind U1 snRNA, and U1 snRNPs containing only the core
snRNP proteins has been demonstrated (18). Recent studies with
SNP1, the Saccharomyces cerevisiae U1-70K homolog, indicate
*To whom correspondence should be addressed. Tel: +49 6421 28 6240; Fax: +49 6421 28 7008; Email: luehrmann@imt.marburg.de
 Nucleic Acids Research, 1996, Vol. 24, No. 234616
that contacts between 70K and other U1 proteins are sufficient for
the formation of functional U1 snRNPs (19). The 70K protein
also exhibits structural features, including regions rich in serine
and arginine residues, characteristic of the SR family of essential
splicing factors (reviewed in 20).
In contrast to U1-70K and U1-A, the U1-specific C protein
does not contain an RBD and its association with the U1 snRNP
appears to be mediated primarily by protein–protein interactions
(21,22). Binding studies carried out with U1-C deletion mutants
have shown that the N-terminal 45 amino acids suffice for its
association with the U1 snRNP (22). Interestingly, this region of
the U1-C protein contains a zinc finger-like motif which appears
to be essential for binding, since point mutations in the cysteine
and histidine residues of this putative zinc finger abolish U1-C
binding (22). The association of U1-C with the U1 snRNP
requires the presence of the N-terminal region of the 70K protein,
as well as one or more Sm protein (18). More recent in vitro
studies have demonstrated that the U1-C protein can form
homodimers; U1-C dimerization also requires amino acids
located in its N-terminal domain (23).
The U1 snRNP appears to function primarily during the early
steps of splicing complex formation. Its main role is the recognition
of the 5′ splice site which appears to be a nucleation event for
spliceosome assembly. While U1 snRNP function relies heavily
upon base pairing interactions of the U1 snRNA, protein compo-
nents have also been shown to contribute to its activity. A general
role for U1-specific proteins was initially suggested by splicing
complementation studies in Xenopus oocytes using mutant U1
snRNAs; several mutants which did not support the stable
association of U1-specific proteins were unable to restore splicing
activity to oocytes that had been depleted of their endogeneous U1
snRNA (24). The first indication that a stable U1/5′ splice site
interaction is mediated by U1 snRNP proteins was provided by
studies demonstrating that mild proteolysis of the mammalian U1
particle inhibits its association with the 5′ splice site (25). Consistent
with this observation, filter binding and gel mobility shift assays
have provided evidence that the U1-C protein can augment the
binding of the U1 snRNP to the 5′ splice site (26,27). The splicing
factor ASF/SF2 has also been shown to enhance the interaction of
U1 with the 5′ splice site; this enhancement appears to involve an
interaction between the SR domain of ASF/SF2 and that of the
U1-70K protein (28).
The bulk of functional information regarding the mammalian
U1-specific proteins has been obtained by studies carried out with
highly purified components in the absence of splicing extract. Here
we have investigated the function of the mammalian U1-specific
proteins in both splicing and early splicing complex formation, using
U1-depleted splicing extracts and either in vitro reconstituted or
biochemically purified U1 snRNPs. Complementation studies
performed with purified U1 snRNPs lacking one or more of the
U1-specific proteins demonstrated that the U1-C protein, but not
U1-A, enhances the formation of early spliceosomal complexes.
Mutagenesis experiments indicated that the N-terminal 60 amino
acids of the U1-C protein are sufficient for this enhancement.
MATERIALS AND METHODS
Preparation of snRNPs and native snRNP proteins
Nuclear extracts were prepared from HeLa cells (Computer Cell
Culture Center, Mons) as described (29). Native U1 snRNPs or
U1 snRNPs specifically lacking either the U1-A (∆A), U1-A and
-C (∆A,C) or U1-A -C, and -70K proteins (core U1 snRNPs) were
isolated from HeLa nuclear extract by anti-m3G immunoaffinity
chromatography followed by Mono Q chromatography (30).
Core U1, ∆A, and ∆A,C particles contained maximally 5% of
each of the depleted U1-specific proteins. Native, RNA-free snRNP
proteins (TPs) were isolated from a mixture of immunoaffinity
purified U1, U2, U5 and U4/U6 snRNPs by dissociation in the
presence of EDTA and the anion exchange resin DE53 (31). HeLa
U1-A and U1-C proteins were isolated from native snRNP
proteins by Mono S chromatography as previously described
(18). Recombinant his-tagged U1-C proteins were constructed
and purified as described previously (23). The substitution
mutant (s28/29) was constructed in essentially the same manner.
Preparation of snRNAs and pre-mRNAs
HeLa U1 and U2 snRNAs were isolated from purified snRNPs as
described previously (31). In vitro transcribed human U1 snRNA
was prepared from PstI linearized pHU1a (32). Wild-type and
mutant Xenopus U1 snRNAs were prepared by in vitro transcrip-
tion of BamHI linearized plasmids with T7 polymerase (15). U1
snRNAs were transcribed in the presence of 1 mM chemically
synthesized GpppG, ApppG, m7GpppG or m3GpppG (as indicated)
and 0.1 mM GTP and were purified by denaturing polyacrylamide
gel electrophoresis. Radiolabeled MINX (33) and pSP62∆i (34)
pre-mRNA, with a specific activity of 2.5 × 106 c.p.m./pmol,
were transcribed in vitro in the presence of GpppG essentially as
described (35). 5′ and 3′ MINX pre-mRNAs, with a specific
activity of 6.25 × 106 c.p.m./pmol, were transcribed from HindIII
linearized pMINX and BamHI linearized p3′MINX. p3′MINX
was generated by isolating a HindIII–BamHI fragment from
pMINX and subcloning into pGEM4.
U1 snRNP depletion and splicing complementation
U1-depleted nuclear extract was prepared by affinity selection with
a biotinylated 2′-O-methyl RNA oligonucleotide and streptavi-
din–agarose beads (36). An oligonucleotide complementary to
U1 snRNA nucleotides 1–13 with the following sequence was
used: 5′-GCCAGGUAAGUAUdC*dC*dC*dC*dT-3′ (where dC*
denotes a biotinylated 2′-deoxycytidine and A, U, G and C represent
2′-O-methyl-ribonucleotides). Titration experiments and Western
blotting indicated that 97.5% of the U1 snRNA, and 95% of
each of the U1-specific proteins A, C and 70K, had been removed
from the U1-depleted extract. Splicing reactions (12.5 µl) were
incubated for 60 min at 30C and typically contained 35%
extract, 45 mM KCl, 2.5 mM MgCl2, 2.0 mM ATP, 10 mM
creatine phosphate and 12 fmol 32P-labeled pSP62∆i pre-mRNA
(3 × 104 c.p.m.). For complementation of U1-depleted extract, 0.6
pmol (200 ng) of Mono Q purified HeLa U1 snRNP were added
directly to the reaction mixture. Complementation with in vitro
reconstituted particles was accomplished by combining 1.8 pmol
(100 ng) of authentic or in vitro transcribed U1 snRNA and 3.8 pmol
(750 ng) of purified native snRNP proteins. This mixture was
incubated for 30 min at 30C in the presence of splicing reactions
lacking pre-mRNA, and splicing was initiated by the addition of
the pre-mRNA. No differences in complementation efficiency
were observed when reconstitution was carried out either directly
in splicing extract or by additionally pre-incubating in the absence
of extract. Splicing intermediates and products were isolated by
phenol/chloroform extraction followed by ethanol precipitation
and analysed on 14.0% polyacrylamide–7 M urea gels.
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Figure 1. The U1 snRNP depletion/complementation assay. The depletion of U1 snRNPs from nuclear extract through a biotinylated 2′-O-methyloligoribonucleotide
and streptavidin–agarose, and reconstitution of U1 snRNPs from U1 snRNA and purified snRNP proteins (TPs) are shown schematically. The association of
stoichiometric amounts of U1-A, but only small amounts of U1-70K, with the U1 snRNA was confirmed by immunoprecipitation experiments with monoclonal
antibodies specific for either the U1-A or U1-70K protein.
E complex assays
E complex formation was assayed by gel filtration on Sephacryl
S-500 (6). Splicing extracts were initially depleted of ATP and
magnesium by dialysis and subsequent incubation at room
temperature for 30 min. Under these conditions no A complex
formation was observed by native gel electrophoresis after a 30 min
incubation at 30C. Standard E complex reactions (75 µl)
contained 30% splicing extract, 45 mM KCl and 0.18 pmol (4.5 ×
105 c.p.m.) of 32P-labeled MINX pre-mRNA and were incubated
at 30C for 25 min. Complexes were fractionated on a 60 × 0.9 cm
column at a flow rate of 10 ml/h, and the amount of radioactivity
present in 350 µl fractions was determined by Cherenkov counting.
Assays performed with 5′ or 3′ MINX pre-mRNA contained
72 fmoles (4.5 × 105 c.p.m.) of radiolabeled transcript. For
complementation of U1-depleted extracts, 4 pmol of the indicated
Mono Q purified U1 snRNPs were added either directly to the
reaction mixture or after a 30 min incubation on ice with 20 pmol
of Mono S purified or recombinant HeLa U1-A or U1-C protein,
as indicated. For in vitro reconstitution studies, 600 ng of U1
snRNA and 3.75 µg native snRNP proteins (in a total of 3 µl) were
incubated for 30 min at 30C prior to incubation with extract.
RESULTS
In vitro reconstituted U1 snRNPs are active in splicing
As a potential means to investigate the function of the mammalian
U1-specific proteins in pre-mRNA splicing, we established an in
vitro reconstitution/splicing complementation system for HeLa
U1 snRNPs (depicted schematically in Fig. 1). HeLa nuclear
extracts specifically depleted of U1 snRNPs were prepared by
affinity selection with a biotinylated 2′-O-methyl RNA oligo-
nucleotide complementary to nucleotides 1–13 of the U1 snRNA.
Mock-depleted extract was handled in an identical manner,
except that oligonucleotide was omitted. Reconstitution of U1
snRNPs was carried out by incubating purified U1 snRNA and
native snRNP proteins (TPs) in the presence of splicing extract.
TPs, which are essentially free of any snRNA, consist of the
snRNP Sm proteins, B, B′, D1, D2, D3, E, F and G, and the
U1-specific proteins A and C, but only trace amounts of U1-70K
(31,37). Since the association of U1-C is strictly dependent on the
presence of the U1-70K protein (18), in vitro reconstituted U1
snRNPs thus consist predominantly of the snRNP Sm proteins
and the U1-A protein. Due to low levels of the U1-70K protein
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Figure 2. Complementation of U1-depleted extracts with U1 snRNPs
reconstituted in vitro. Reconstitutions were performed in the presence of extract
as described in the Materials and Methods. In vitro splicing reactions were
performed with mock (lane 1), U1-depleted (lane 2) or U1-depleted extract plus
the following: 0.8 pmol (200 ng) Mono Q purified U1 snRNPs (lane 3), 1.0 or
2.0 pmol each of purified HeLa U1 snRNA (lanes 4–5), HeLa U2 snRNA (lanes
6–7), or U1 snRNA plus 750 ng (∼4.0 pmol) of purified snRNP proteins (TPs)
(lanes 8–9). The addition of TPs alone did not restore splicing to a significant
extent. Splicing was performed for 60 min with SP62∆i pre-mRNA as
described in the Materials and Methods. Splicing intermediates and products as
well as unspliced pre-mRNA (indicated at the right) were fractionated on a 14%
polyacrylamide–7 M urea gel and visualized by autoradiography. All U1-depleted
extracts typically exhibited a low level of residual splicing activity (∼10–20%
of mock extract activity).
in TPs and U1-depleted extract, a small amount of wild-type U1
snRNP is also reconstituted (data not shown).
Splicing of an adenovirus major late II pre-mRNA (pSP62∆i)
was significantly reduced in U1-depleted extract (Fig. 2, lanes
1–2). However, the addition of a physiological amount (200 ng)
of highly purified U1 snRNP restored splicing to mock extract
levels (Fig. 2, lane 3), demonstrating that the observed reduction
in activity is due specifically to the absence of U1 snRNPs.
Splicing was also restored if 2 pmol of purified HeLa U1 snRNA
(a 2-fold excess as compared to the mock extract level) was added
(Fig. 2, lane 5). U2 snRNA, on the other hand, did not
complement splicing (lanes 6–7), indicating that this effect is
specific for U1 snRNA. Splicing complementation was, however,
significantly enhanced, especially at the lower U1 snRNA
concentration, if native snRNP proteins were added to the
reconstitution mixture (compare lanes 4–5 with 8–9). TPs alone
had little or no effect on the splicing activity of U1-depleted
extract (Fig. 3, lane 23). Since the extent of U1 snRNA
degradation was significantly reduced when TPs were present
during reconstitution and in vitro splicing, the TP-induced
enhancement of splicing complementation appeared to be
primarily the result of increased U1 snRNA stability (data not
shown). In sum, splicing could be restored by the addition of
purified U1 snRNA alone, but even more efficiently by the
combination of U1 snRNA and purified snRNP proteins.
U1 snRNPs reconstituted from in vitro transcribed snRNA
can complement splicing
We next tested whether the splicing activity of U1-depleted
extract could be restored by in vitro transcribed U1 snRNA.
Concurrently, the role in splicing of the U1 snRNA 5′ cap was
investigated by comparing in vitro transcribed RNAs possessing
various cap structures. Synthetic HeLa U1 snRNA containing an
m3G or non-physiological ApppG cap (either alone or with TPs)
restored splicing to U1-depleted extract as efficiently as U1
snRNA isolated from HeLa U1 snRNPs (compare lanes 13–14,
17–18 and 19–20). In contrast, U1 snRNAs containing either an
m7G or GpppG cap not only were unable to complement splicing
(lanes 15–16 and 21–22), but also, in the absence of TPs, inhibited
the activity of the mock extract as well as the residual splicing
activity of the U1-depleted extract (compare lane 1 with lanes 3
and 9, and lane 12 with lanes 15 and 21). Since the stability of the
m7G- and GpppG-capped U1 snRNAs was similar to that of the
m3G- and ApppG-capped ones (data not shown), the decreased
complementation efficiency of these RNAs cannot be attributed
to an increase in their turnover. Rather, the latter result is
consistent with previous data demonstrating that short RNAs
possessing an m7G or GpppG cap can inhibit splicing by
competing for proteins (i.e., CBP20 and CBP80) which normally
bind the m7G cap of the pre-mRNA (38). Thus, although there is
no absolute requirement for an m3G cap, not all cap structures are
compatible with U1 snRNP splicing activity in vitro.
Deletion of stem–loop I or II of the U1 snRNA does not
affect the splicing activity of reconstituted U1 snRNPs
The ability to complement splicing with in vitro transcribed U1
snRNA allowed us to investigate the effect of U1 snRNA mutation
on the activity of in vitro reconstituted U1 snRNPs. Since we were
particularly interested in investigating the function of the U1-specific
proteins, we tested the activity of Xenopus U1 snRNA mutants
which lacked the RNA binding sites of the U1-70K and U1-A
protein (mutants A and B, respectively). As shown in Figure 4,
in vitro transcribed wild-type Xenopus U1 snRNA restored splicing
activity to U1-depleted extract (lanes 6–7), albeit slightly less
efficiently than U1 snRNA isolated from HeLa U1 snRNPs (lanes
4–5). As compared to wild-type, deletion of stem–loop I (mutant
A) or stem–loop II (mutant B) had no significant effect on the
complementation efficiency of in vitro reconstituted U1 snRNPs
(Fig. 4, lanes 8–11). Thus, reconstitution of U1 snRNPs active in
splicing does not require the presence of stem–loop I or II. This in
turn suggests that either U1-70K and U1-A are dispensible for U1
snRNP function in vitro or, alternatively, that these proteins can
functionally associate with the U1 snRNP by other means (e.g. by
protein–protein interactions).
E complex formation in U1-depleted extracts can be
complemented with purified or in vitro reconstituted
U1 snRNPs
Since substoichiometric amounts of the U1 snRNP may suffice
for the complete restoration of splicing activity, we reasoned that
alterations in the U1 snRNP that affect its function might be more
readily detected by an assay which directly measures the amount
of functional snRNPs present. We thus analyzed the formation of
the earliest detectable functional splicing complex, the E
complex, by gel filtration (6). Due to inefficient splicing complex
formation with SP62∆i transcripts (data not shown), E complex
assays were performed with MINX pre-mRNA, which is also a
derivative of the adenovirus major late II transcript. As compared
to the mock-depleted extract, E complex formation was severely
reduced in U1-depleted extract; predominantly pre-mRNA/
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Figure 3. Complementation of U1-depleted extracts with in vitro transcribed U1 snRNA. U1 snRNA was transcribed in vitro with either an m2,2,7GpppG (m3G), m7GpppG
(m7G), GpppG or ApppG cap as described in the Materials and Methods. In vitro splicing reactions were performed with mock (lanes 1–11) or U1-depleted extract (lanes
12–23) either alone (lanes 1 and 12) or after the addition of various U1 snRNAs/snRNPs. 100 ng of the following RNAs were added either alone or with 750 ng of purified
snRNP proteins (TPs; as indicated above each lane): U1 snRNA purified from U1 snRNPs (HeLa U1 RNA; lanes 2, 13 and 14) or in vitro transcribed U1 containing an
m7G (lanes 3–4 and 15–16), m3G (lanes 5–6 and 17–18), ApppG (lanes 7–8 and 19–20) or GpppG cap (lanes 9–10 and 21–22). In lanes 11 and 23, 750 ng of TPs alone
were added to the reaction mixture. In vitro reconstitution and in vitro splicing assays were performed as described in the legend of Figure 2.
Figure 4. Complementation of U1-depleted extracts with U1 snRNPs
reconstituted from U1 snRNAs lacking stem–loop I or II. In vitro splicing
assays were performed with mock (lane 1), U1-depleted (lane 2) or U1-depleted
extract plus 200 ng of HeLa U1 sRNP (lane 3) or 2.0 pmol of the following U1
snRNAs, either alone or with 750 ng TPs (as indicated above each lane): U1
snRNA isolated from HeLa U1 snRNPs (lanes 4 and 5), or in vitro transcribed,
wild-type (lanes 6 and 7), mutant A (lanes 8 and 9) or mutant B (lanes 10 and
11) Xenopus U1 snRNA. Mutant A lacks nucleotides 17–47 which comprise
stem–loop I of the U1 snRNA, whereas mutant B lacks nucleotides 50–91
which form stem–loop II (24). In vitro reconstitution and in vitro splicing assays
were carried out as described in the legend of Figure 2.
hnRNP protein complexes (i.e., H complexes) were formed (Fig.
5A). The addition of physiological amounts of highly purified U1
snRNPs shifted the gel filtration profile of the U1-depleted extract
to that of the mock extract (Fig. 5A), indicating that the reduction
in early splicing complex formation is specifically due to the
absence of U1 snRNPs. E complex formation could also be
partially restored by the addition of U1 snRNPs reconstituted
from TPs and either authentic HeLa or in vitro transcribed
Xenopus U1 snRNA (Fig. 5B). The addition of in vitro transcribed
Xenopus U1 snRNA or TPs alone had little or no effect on
complex formation (data not shown). The ratio of E to H complex
did not change significantly, as compared to wild-type Xenopus
U1 snRNA, when complementation was performed with recon-
stituted U1 snRNPs lacking stem–loop I or II (mutants A and B;
Fig. 5C). These results thus provide additional evidence that
functional U1 snRNPs can be reconstituted even if the U1 snRNA
binding sites for the U1-70K and U1-A protein are deleted.
Deletion of the 5′ end of the U1 snRNA, on the other hand, led
to a marked decrease in E complex formation (data not shown).
The latter is consistent with the previous observation that deletion
of the 5′ splice site leads to a dramatic reduction in E complex
formation (7) and supports the idea that the early splicing
complexes which we detect are indeed functional ones.
The U1-C, but not the U1-A, protein stimulates E complex
formation in U1-depleted extracts
One drawback of studies performed with reconstituted particles
is the presence of very large amounts of U1-A and U1-C, and
smaller amounts of U1-70K, in the reconstitution mixture. Since
conclusive results regarding the function of the U1-specific
proteins could not be obtained with in vitro reconstituted particles,
we tested the activity of equimolar amounts of biochemically
purified HeLa U1 snRNPs lacking either the U1-A (∆A U1
snRNPs), U1-A and U1-C (∆A,C U1 snRNPs) or U1-A, U1-C and
U1-70K proteins (core U1 snRNPs) (30). As shown in Figure 6A,
wild-type U1 snRNPs and those lacking the U1-A protein
complemented E complex formation to a similar extent. Particles
lacking both the U1-A and U1-C protein only partially complem-
ented E complex formation, whereas those lacking all three
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Figure 5. Complementation of E complex formation in U1-depleted extracts with in vitro reconstituted U1 snRNPs. Mock or U1-depleted extract (Depl), lacking ATP
and magnesium, was incubated at 30C for 25 min in the presence of 450 000 c.p.m. MINX pre-mRNA and then fractionated by gel filtration on Sephacryl S-500
as described in the Materials and Methods. The peaks containing E and H complexes are indicated above each column profile. The peak in fractions 40–50 is the void
volume, whereas that in fractions 90–100 is degraded RNA. For complementation of U1-depleted extracts, 4 pmol of Mono Q purified U1 snRNP (A) or U1 snRNPs
reconstituted from 600 ng of the indicated U1 snRNA and 4 µg of purified snRNP proteins (TPs) (B and C) were added. RNA designated U1 was isolated from HeLa
U1 snRNPs whereas Xe or Mut A and B U1 snRNAs were transcribed in vitro and are from Xenopus.
Figure 6. The U1-C protein stimulates E complex formation in U1-depleted extracts. E complex assays were performed as described in the legend to Figure 5.
Complementation assays were performed in U1-depleted extract (Depl) with 4 pmol of Mono Q purified wild-type (A), ∆A (A), ∆A,C (B) or core (B) U1 snRNPs,
or with ∆A,C U1 snRNPs that had been pre-incubated for 30 min on ice with 20 pmol of Mono S purified HeLa U1-A or U1-C protein (C). The peaks containing
E and H complexes are indicated above each column profile.
U1-specific proteins were inactive (Fig. 6B). These results thus
suggest that both U1-70K and U1-C, but not U1-A, contribute to
the formation of early spliceosomal complexes. To directly
determine whether E complex formation is enhanced by the U1-C
protein, complementation was performed with ∆A,C U1 snRNPs
that had been preincubated with biochemically purified U1-C or
U1-A protein. While the complementation efficiency of ∆A,C
particles was only slightly enhanced by the addition of purified
U1-A protein, the addition of U1-C protein shifted the ratio of E
to H complex to that of wild-type U1 snRNPs (Fig. 6C). The
addition of the U1-C or U1-A protein alone had no effect on E
complex formation (data not shown). These results thus clearly
demonstrate that the U1-C protein, in the presence of the U1
snRNP, enhances the assembly of early splicing complexes.
The U1-C protein stimulates splicing complex assembly
on the 5′ portion of the pre-mRNA
Previous studies have demonstrated that specific ATP-indepen-
dent complexes, denoted E5′ and E3′, assemble on RNAs
containing only the 5′ or 3′ portion of a pre-mRNA (7). E5′
complexes contain predominantly U1 snRNPs, whereas E3′
complexes are enriched in the splicing factor U2AF (7). To test
whether the U1-C protein acts at the 5′ or 3′ splice site, RNAs
consisting of the 5′ or 3′ half of the MINX pre-mRNA were
prepared and their ability to form E5′ and E3′ complexes,
respectively, was tested in mock and U1-depleted extract.
Consistent with the known composition of E3′ complexes (i.e.,
they are for the most part devoid of U1 snRNPs), no significant
difference in E3′ assembly was detected in mock versus
U1-depleted extract (data not shown). In contrast, with the 5′
MINX transcript, an equal amount of E5′ and H complex was
observed with mock-depleted extract, but essentially only H
complex with U1-depleted extract (Fig. 7A). As observed with
full-length MINX, the addition of physiological amounts of either
wild-type or ∆A U1 snRNPs shifted the gel filtration profile of
U1-depleted extract to that of the mock-depleted extract (Fig. 7A
and B). Addition of ∆A,C U1 snRNPs, on the other hand, resulted
in only a partial shift (Fig. 7B). However, pre-incubation of ∆A,C
U1 snRNPs with the U1-C protein enhanced E5′ assembly such
that the levels of E5′ and H complex were indistinguishable from
those of the mock-depleted extract (Fig. 7C). In contrast, addition
of the U1-A protein had no effect on the complementation activity
of ∆A,C U1 snRNPs (Fig. 7C). Moreover, addition of the U1-C
protein alone also had no significant effect on E5′ complex
formation (data not shown). Thus, the U1-C protein stimulates
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Figure 7. The U1-C protein stimulates splicing complex formation on an RNA containing the 5′ splice site. E complex assays were performed as described in the legend
to Figure 5, except mock or U1-depleted extract (Depl) was incubated with the 5′ half of the MINX pre-mRNA. Complementations were performed with 4 pmol of
Mono Q purified wild-type (A), ∆A (B), ∆A,C (B) U1 snRNPs or with ∆A,C U1 snRNPs that had been pre-incubated for 30 min on ice with 20 pmoles of Mono S
purified HeLa U1-C or U1-A protein (C). The peaks containing E5′ or H complexes are indicated above each column profile.
interactions occurring on the 5′ half of the MINX pre-mRNA,
namely those between the U1 snRNP and the 5′ splice site, even
in the absence of a 3′ splice site.
The N-terminal domain of the U1-C protein is
necessary and sufficient for its activity in splicing
complex formation
To determine whether distinct regions of the U1-C protein are
necessary and/or sufficient for the stimulation of E complex
formation, we tested the activity of several HeLa U1-C mutants.
To this end, histidine-tagged U1-C deletion and substitution
mutants were constructed and over-expressed in E.coli (Fig. 8A).
While the addition of ∆A,C U1 snRNPs alone only partially
enhanced E complex formation in U1-depleted extract (Fig. 8B),
preincubation with wild-type recombinant U1-C protein led to a
significant increase in the ratio of E to H complex formed
(Fig. 8B). Surprisingly, deletion of the C-terminal 99 amino acids
of the U1-C protein did not significantly reduce complementation
efficiency, indicating that the N-terminal 60 amino acids are
sufficient for activity. In contrast, deletion of amino acids 1–29
abolished the ability of the U1-C protein to enhance E complex
formation (Fig. 8B). These results thus demonstrate that residues
within the first 29 amino acids of the U1-C protein are essential
for its activity. We next tested the activity of two point mutants,
(s25) and (s28/29), which exhibit both reduced binding and
dimerization activity (23, data not shown). As shown in
Figure 8C, substitution of the cysteine at position 25 with a serine
led to only a slight decrease in the ratio of E to H complex, while
substitution of arginine and lysine at positions 28 and 29 with
glycine and serine, respectively, abolished the ability of U1-C to
enhance E complex formation. These results thus indicate that the
latter amino acids play an important role in the U1-C protein-me-
diated augmentation of E complex assembly.
DISCUSSION
We have established an in vitro reconstitution/splicing comple-
mentation system for HeLa U1 snRNPs which should facilitate
future investigation of both structural and functional aspects of the
U1 snRNP. Reconstitution/complementation systems have thus
now been described for each of the mammalian spliceosomal
snRNPs and a number of comparisons can be made among them
(37,39,40). Restoration of the splicing activity of U1-depleted
extracts could be achieved by the addition of an excess of purified
U1 snRNA alone (Fig. 2), suggesting that sufficient amounts of
those proteins required for the assembly of functional U1 snRNPs
are present in U1-depleted extracts. While similar results were
previously reported for U4-depleted extracts (39), U2- or U5-
depleted extracts could not be complemented by the addition of U2
or U5 snRNA alone. Rather, reconstitution of functional U2 or U5
snRNPs required the addition of purified snRNP Sm proteins (37).
In this respect, it is interesting to note that U1 and U4/U6 snRNPs,
which contain only three and two particle-specific proteins,
respectively, are relatively simple RNP complexes as compared to
U2 and U5 snRNPs which contain eleven and nine particle-specific
proteins, respectively. Functional reconstitution of the former may
thus be more readily achieved in the presence of relatively low
levels of Sm proteins or, alternatively, may not be strictly
dependent on their presence (39).
U1 snRNPs reconstituted from in vitro transcribed U1 snRNA
were as active in E complex formation and splicing as those
reconstituted from U1 snRNA that had been isolated from U1
snRNPs (Figs 3 and 5). Since in vitro transcribed U1 is devoid of
modified internal nucleotides, and it is unlikely that modification
occurs during reconstitution and in vitro splicing, the three
pseudouridines and two 2′-O-methylated nucleotides normally
present at the 5′ end of U1 snRNA appear to be dispensible for U1
snRNP function in splicing. The ability to restore splicing to
U1-depleted extract with synthetic U1 snRNA indicates that it
may be possible to reconstitute functional U1 snRNPs containing
photoactivateable nucleosides (e.g. 4-thiouridine). The in vitro
reconstitution/splicing complementation system described here
could thus potentially be used to study the interactions of the U1
snRNP with other components of the splicing reaction and
thereby further our understanding of the three-dimensional
architecture of the spliceosome.
As previously reported for the U5 snRNP (37), a modified 5′
cap structure (i.e., m3G) was also dispensible for the activity of
U1 snRNPs in in vitro splicing (Fig. 3). However, apparently due
to competition for the m7G cap-binding proteins CBP20 and
CBP80, the presence of an m7G or GpppG cap led to inhibition
of the splicing reaction. Since we had previously reported that
m7G-capped U5 snRNPs could restore splicing activity to a
U5-depleted extract (37), and the amount of m7G-capped U5
snRNA used was only 2-fold less than the amount of m7G-capped
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Figure 8. The N-terminal domain is necessary and sufficient for U1-C activity. The recombinant U1-C proteins used in E complex assays are shown schematically in
(A). The shaded box represents the methionine/proline-rich C terminus which begins at position 61. In the substitution mutant (s28/29), the arginine and lysine at positions
28 and 29 have been substituted by glycine and serine, respectively, and in (s25), the cysteine at position 25 has been replaced by a serine. The ability of each of these
proteins to associate with U1 snRNPs and to form dimers is summarized at the right (22,23). E complex assays (B–D) were performed as described in the legend to Figure
5. Complementation of U1-depleted extract (Depl) was performed with 4 pmol of Mono Q purified ∆A,C snRNPs (B) or with ∆A,C U1 snRNPs that had been
pre-incubated for 30 min on ice with 20 pmol of the following recombinant U1-C proteins: wild-type (B), the deletion mutant (1–60) (C), the deletion mutant (30–159)
(C), the substitution mutant (s28/29) (D), or the substitution mutant (s25) (D). The position of E and H complexes is indicated above each column profile.
U1 snRNA used here, we initially considered whether this
inhibitory effect might be specific for the U1 snRNP. A direct
comparison of the inhibitory effects of m7G-capped U1 and U5
snRNPs on in vitro splicing indicated that both compete at a
comparable level for the binding of the cap-binding proteins (data
not shown). The detrimental effect of m7G-capped snRNPs on
splicing thus appears to be more pronounced in U1-depleted
extracts. Since the cap-binding proteins have also been shown to
stimulate E complex formation (41,42), it is perhaps not
surprising that the effects of competition for these proteins are
more readily detected in a system where E complex assembly is
severely compromised due to the decreased level of U1 snRNPs.
Alternatively, since CBP20 and CBP80 have been proposed to
interact either directly or indirectly with components of the U1
snRNP (41), it is conceivable that they have been partially
co-depleted with the U1 snRNP. The deleterious effect of
m7G-capped U1 or U5 snRNPs on splicing suggests that the
requirement of an m3G cap for the import of the spliceosomal
snRNPs into the nucleus may have evolved, at least in part, to
prevent the accumulation of m7G-capped snRNPs in the nucleus.
Whereas in vitro splicing activity could be restored by U1
snRNA alone, complementation of E complex assembly required
both U1 snRNA and TPs. This result could be explained by
differences in the nature of these two assays. In contrast to in vitro
splicing, the E complex assay is a binding assay and, therefore,
should directly reflect the amount of functional U1 snRNP that is
reconstituted. Since E complex formation may not be rate limiting
for in vitro splicing, the reconstitution of small amounts of
functional U1 snRNP, while having little impact on the overall
level of E complex formation, may suffice for the complete
restoration of splicing. In addition, the amount of E complex
detected by gel filtration appears to be very dependent upon the
stability of the complexes which are formed (7). Structural
alterations in the U1 snRNP which reduce the amount of E
complex detected by gel filtration (e.g., the removal of the U1-C
protein), could thus primarily influence the stability, rather than
the assembly, of these complexes. Thus, not only quantitative, but
also qualitative differences in the U1 snRNP should be more
readily apparent in the E complex assay. This could also explain
why, in contrast to in vitro splicing, E complex formation was
only partially restored by in vitro reconstituted U1 snRNPs
(Fig. 5B). It is at present not clear, however, whether this partial
complementation is due to the reconstitution of insufficient
amounts of U1 snRNPs or, alternatively, to the formation of
particles that are unable to support stable E complex formation,
for example due to limiting amounts of the U1-70K protein which
would limit binding of the U1-C protein.
Complementation studies with U1 snRNPs reconstituted from
U1 snRNA deletion mutants indicated that functional U1 snRNPs
can be formed even after extensive mutagenesis of the U1
snRNA, including deletion of stem–loop I or II (Figs 4 and 5).
These results are somewhat surprising given the fact that these
mutations significantly inhibited the ability of U1 snRNPs to
complement splicing in Xenopus oocytes whose endogeneous U1
snRNA had been inactivated by oligonucleotide-directed RNase
H cleavage (24). The basis for this difference is not clear, but may
simply reflect differences in the assay systems employed. The
ability of U1 snRNPs lacking stem–loop I or II to complement
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splicing suggests, at first glance, that U1-A and U1-70K are
dispensible for U1 snRNP function. However, there is a
significant amount of evidence suggesting that these proteins can
stably associate with the U1 snRNP solely via protein-protein
interactions (16,18,24). In addition, recent studies carried out in
S.cerevisiae indicated that contacts between the yeast 70K
homologue and other U1 snRNP proteins are sufficient for the
assembly of a functional U1 snRNP particle (19). Our results are
thus consistent with the idea that, despite the removal of their
primary RNA binding site, the U1-70K and U1-A proteins can
stably and functionally associate with the U1 snRNP.
Evidence that the U1-C, but not U1-A, protein can enhance E
complex formation and/or stability was provided by comple-
mentation studies with biochemically purified U1 snRNPs
lacking one or more of the U1-specific proteins (Figs 6 and 7).
These results are consistent with previous studies, performed in
the absence of nuclear extract,which indicated that the U1-C
protein enhances the interaction of the U1 snRNP with the 5′
splice site (26,27). The U1-C protein could enhance E complex
formation by interacting directly with the 5′ splice site. Indeed, it
has recently been shown that U1-C can be crosslinked to a short
oligonucleotide containing a 5′ splice site (43). Alternatively, the
binding and dimerization of the U1-C protein could indirectly
enhance interactions with the pre-mRNA by affecting the overall
structure of the U1 snRNP. The reduced activity of ∆A,C,70K
(core) U1 snRNPs as compared to ∆A,C U1 snRNPs further
suggested that the U1-70K protein also contributes to the
formation and/or stability of E complexes. Consistent with this
hypothesis, a stable, ASF/SF2-mediated interaction between U1
and the 5′ splice site appeared to involve an interaction between
the U1-70K protein and ASF/SF2 (27,28). However, since U1-C
protein binding is dependent on the U1-70K protein, the reduced
activity of core U1 snRNPs as compared to ∆A,C U1 snRNPs
could also potentially result from a decrease in the amount of
U1-C association. Since neither U1 snRNPs specifically depleted
of the U1-70K protein nor sufficient amounts of purified U1-70K
protein were available, it was not possible to directly test the
effect of this U1-specific protein on E complex formation.
Mutagenesis of the U1-C protein provided strong evidence that its
N-terminal domain is necessary and sufficient for its function during
the early stages of spliceosome assembly (Fig. 8). A functional role
for the N-terminal but not C-terminal domain in E complex
formation is consistent with recent studies demonstrating that solely
amino acids in the N-terminal domain of the protein have been
evolutionarily conserved from yeast to man (44). However, since we
have only measured effects on E complex formation, we cannot rule
out that the methionine/proline-rich C-terminal domain is involved
in subsequent steps of the splicing process. The U1-C N-terminus
contains residues essential for the interaction of U1-C with the U1
particle, as well as those required for dimerization (22,23). Due to
the inability to overexpress sufficient amounts of point mutants
which are solely deficient in U1 snRNP association, we cannot
conclude at present whether a stable U1-C/U1 snRNP interaction is
essential for the promotion of E complex assembly. However, given
that the U1-C protein enhances the interaction of U1 with the 5′
splice site, it is reasonable to assume that the stabilization of this
interaction requires the stable association of U1-C with the U1
snRNP. Complementation studies performed with point mutants
demonstrated that the arginine and lysine present at positions 28 and
29, respectively, are essential for U1-C activity; substitution of the
cysteine at position 25 with serine, on the other hand, only slightly
reduced its ability to stimulate E complex formation. Since both
mutations have been reported to diminish, but not abolish U1-C
dimerization (23, data not shown), these results suggest that
dimerization, while not absolutely essential, may still contribute to
the activity of the U1-C protein during E complex formation.
However, since these mutants also exhibit reduced binding (see
Fig. 8), we cannot exclude that their phenotypes reflect, at least in
part, their decreased ability to interact with the U1 particle. A more
detailed mutational analysis of the U1-C protein should, in the
future, allow us to more precisely define those amino acids essential
to U1-C function. This system should thus allow a finer examination
of those factors influencing the formation of the first functionally
important complex in the spliceosome assembly pathway.
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